198 related articles for article (PubMed ID: 35131874)
1. Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract][Full Text] [Related]
2. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
3. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
4. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
5. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton J; Blagih J; Ennis D; Leung E; Dowson S; Farquharson M; Tookman LA; Orange C; Athineos D; Mason S; Stevenson D; Blyth K; Strathdee D; Balkwill FR; Vousden K; Lockley M; McNeish IA
Cancer Res; 2016 Oct; 76(20):6118-6129. PubMed ID: 27530326
[TBL] [Abstract][Full Text] [Related]
7. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
8. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
9. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
10. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
11. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
Ghaffari A; Peterson N; Khalaj K; Vitkin N; Robinson A; Francis JA; Koti M
Br J Cancer; 2018 Aug; 119(4):440-449. PubMed ID: 30046165
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of immune related genes in high-grade ovarian serous carcinoma.
Siamakpour-Reihani S; Cobb LP; Jiang C; Zhang D; Previs RA; Owzar K; Nixon AB; Alvarez Secord A
Gynecol Oncol; 2020 Mar; 156(3):662-668. PubMed ID: 31918995
[TBL] [Abstract][Full Text] [Related]
13. Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis.
Casciello F; Kelly GM; Ramarao-Milne P; Kamal N; Stewart TA; Mukhopadhyay P; Kazakoff SH; Miranda M; Kim D; Davis FM; Hayward NK; Vertino PM; Waddell N; Gannon F; Lee JS
Cancer Res; 2022 Apr; 82(7):1208-1221. PubMed ID: 35149587
[TBL] [Abstract][Full Text] [Related]
14. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
[TBL] [Abstract][Full Text] [Related]
15. Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis.
Coward WR; Brand OJ; Pasini A; Jenkins G; Knox AJ; Pang L
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):449-460. PubMed ID: 29053336
[TBL] [Abstract][Full Text] [Related]
16. EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM.
Naskou J; Beiter Y; van Rensburg R; Honisch E; Rudelius M; Schlensog M; Gottstein J; Walter L; Braicu EI; Sehouli J; Darb-Esfahani S; Staebler A; Hartkopf AD; Brucker S; Wallwiener D; Beyer I; Niederacher D; Fehm T; Templin MF; Neubauer H
Mol Cancer Res; 2020 Feb; 18(2):278-286. PubMed ID: 31704732
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
18. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
19. Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer.
Zhang G; Lu J; Yang M; Wang Y; Liu H; Xu C
Cancer Immunol Immunother; 2020 Feb; 69(2):175-187. PubMed ID: 31853576
[TBL] [Abstract][Full Text] [Related]
20. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
